6/7/2013 7:30:34 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Aveo Oncology (AVEO_) will succeed or fail depending on the potential for tivozanib to treat triple-negative breast cancer.
For investors in Aveo, of which I am one, the wait for data from a phase II study in triple negative breast cancer (TNBC) is a long one. Results won't be ready until late 2014 or early 2015. But upon these tivozanib data, the fate of the company rests. On a conference call Wednesday, Aveo outlined future development plans for tivozanib, which include dropping development in kidney cancer (Adam Feuerstein addressed this prickly situation with some strong words) and focusing instead on colon cancer and TNBC. The ongoing phase II study in first-line colon cancer will actually be the first to report data next year, but the odds for success are low.
Help employers find you! Check out all the jobs and post your resume.
comments powered by